
WilmerHale Represents Kala Pharmaceuticals in \$103.5 Million IPO

JULY 27, 2017

On July 25, 2017, Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of two Phase 3 product candidates, KPI-121 1.0% for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease using its proprietary mucus-penetrating particle (MPP) technology, announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters' exercise in full of their option to purchase an additional 900,000 shares, at the public offering price of \$15.00 per share. The exercise of the underwriters' option brought the amount of gross proceeds raised in the offering to approximately \$103.5 million, before underwriting discounts, commissions and estimated expenses of the offering.

The WilmerHale team representing Kala in the transaction was led by [Lia Der Marderosian](#) and included [Ryan Mitteness](#), [Emily Gainor](#), [Alex Civetta](#) and [Heidi Treiber](#).

[Kala's press release is available here.](#)